Eiken Chemical Co., Ltd. engages in the manufacturing and sale of clinical diagnostics and equipment in Japan. It offers microbiological reagents for diagnosis of microorganism infection, such as mediums, antimicrobial susceptibility, and rapid test reagents; urinalysis test strips for occult blood, protein, and glucose; and fecal immunochemical tests for screening of colorectal cancer. The company also provides immunological and serological reagents to detect and monitor infectious disease, rheumatism, inflammation, atrophic gastritis, and prostate specific antigens; and clinical chemistry tests to measure and analyze biological components in blood serum. In addition, it sells reagents and devices of microbiological test for food poisoning bacteria and environmental inspection; and offers nucleic acid amplification method, as well as provides various types of automated analyzers. The company was formerly known as Nihon Eiyokagaku Co., Ltd. and changed its name to Eiken Chemical Co., Ltd. in 1969. Eiken Chemical Co., Ltd. was incorporated in 1939 and is headquartered in Tokyo, Japan.
Stock data | 2023 | Change |
---|---|---|
Price | $15.81 | N/A |
Market Cap | $584.63M | N/A |
Shares Outstanding | 36.97M | 0.03% |
Employees | 754.00 | N/A |
Shareholder Equity | 49.53B | 8.15% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.10 | N/A |
P/S Ratio | 1.96 | N/A |
P/B Ratio | 0.01 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0008 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $297.66M | N/A |
Earnings | $39.46M | N/A |
EPS | 153.86 | N/A |
Earnings Yield | 9.73 | N/A |
Gross Margin | 0.4739 | N/A |
Operating Margin | 0.1723 | N/A |
Net income margin | 0.1326 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $455.89M | N/A |
Total Debt | $29.64M | N/A |
Cash on Hand | $128.32M | N/A |
Debt to Equity | 0.0023 | -7.38% |
Cash to Debt | $4.33 | 10.33% |
Current Ratio | $3.15 | 6.65% |